TW505648B - Preparation of 14-hydroxynormorphinones, oxycodone noroxymorphone, oxymorphone and naltrexone from normorphinones - Google Patents
Preparation of 14-hydroxynormorphinones, oxycodone noroxymorphone, oxymorphone and naltrexone from normorphinones Download PDFInfo
- Publication number
- TW505648B TW505648B TW087116132A TW87116132A TW505648B TW 505648 B TW505648 B TW 505648B TW 087116132 A TW087116132 A TW 087116132A TW 87116132 A TW87116132 A TW 87116132A TW 505648 B TW505648 B TW 505648B
- Authority
- TW
- Taiwan
- Prior art keywords
- items
- benzyl
- morphine
- cyclopropylmethyl
- codeine
- Prior art date
Links
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 title claims abstract description 23
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract description 7
- 229960005118 oxymorphone Drugs 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 44
- 229960002085 oxycodone Drugs 0.000 title abstract description 3
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 title abstract 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 2
- 229960003086 naltrexone Drugs 0.000 title abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims abstract description 107
- 229960005181 morphine Drugs 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 42
- 238000006243 chemical reaction Methods 0.000 claims abstract description 21
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 131
- 229960004126 codeine Drugs 0.000 claims description 83
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 67
- 238000011049 filling Methods 0.000 claims description 63
- -1 4 Chemical compound 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 239000000243 solution Substances 0.000 claims description 53
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 38
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 32
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 31
- 230000002079 cooperative effect Effects 0.000 claims description 31
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 claims description 30
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 28
- 239000011541 reaction mixture Substances 0.000 claims description 25
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 235000019253 formic acid Nutrition 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 20
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 19
- 239000002585 base Substances 0.000 claims description 18
- 230000000875 corresponding effect Effects 0.000 claims description 16
- WLAZIEAWWALKKX-MUMHOZHSSA-N (4r,4ar,7s,7ar,12bs)-9-benzyl-3-methyl-1,2,4,4a,7,7a,10,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C([C@]1(N(CC[C@@]23C4=C5O[C@H]3[C@@H](O)C=C[C@@H]12)C)[H])C4=CCC5(O)CC1=CC=CC=C1 WLAZIEAWWALKKX-MUMHOZHSSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- YPZPXTZKBNWUTF-UHFFFAOYSA-N 14beta-Hydroxy-codein Natural products O1C2C(O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YPZPXTZKBNWUTF-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 235000012149 noodles Nutrition 0.000 claims description 11
- 239000007800 oxidant agent Substances 0.000 claims description 10
- 230000001590 oxidative effect Effects 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- LHTAJTFGGUDLRH-QMVVXIJUSA-N (4r,4as,7s,7ar,12bs)-9-methoxy-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol Chemical compound O[C@H]([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C LHTAJTFGGUDLRH-QMVVXIJUSA-N 0.000 claims description 6
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 claims description 5
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 claims description 5
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- JJGRKZBXASWTLH-JFJMRBLZSA-N (4R,4aR,7aR,12bS)-9-benzyl-9-hydroxy-3-methyl-2,4,4a,7a,10,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound C(C1=CC=CC=C1)C1(CC=C2C[C@@H]3[C@@H]4C=CC([C@H]5[C@@]4(C2=C1O5)CCN3C)=O)O JJGRKZBXASWTLH-JFJMRBLZSA-N 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- XYYVYLMBEZUESM-CMKMFDCUSA-N codeinone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XYYVYLMBEZUESM-CMKMFDCUSA-N 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- SLROTKFSBGWEDD-PDTFXZCISA-N (4r,4ar,7s,7ar,12bs)-3-methyl-1,2,4,4a,7,7a,10,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9,9-triol Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@@]31C1=C2C(O)(O)CC=C1C4 SLROTKFSBGWEDD-PDTFXZCISA-N 0.000 claims description 2
- IWOYJFLNKCFMOS-UHFFFAOYSA-N 2-methylcyclopropan-1-ol Chemical compound CC1CC1O IWOYJFLNKCFMOS-UHFFFAOYSA-N 0.000 claims description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001409 amidines Chemical class 0.000 claims description 2
- 229960000920 dihydrocodeine Drugs 0.000 claims description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 2
- 150000002926 oxygen Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 230000017858 demethylation Effects 0.000 claims 4
- 238000010520 demethylation reaction Methods 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical class 0.000 claims 2
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002140 halogenating effect Effects 0.000 claims 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 2
- JBXSOBGLTCINCO-NGJYPEJPSA-N (4R,4aR,7aR,12bS)-8a,9-dihydroxy-3-methyl-2,4,4a,7a,9,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OC12C(C=CC=3C[C@@H]4[C@@H]5C=CC([C@@H]([C@@]5(C1=3)CCN4C)O2)=O)O JBXSOBGLTCINCO-NGJYPEJPSA-N 0.000 claims 1
- UNIQRGVBLNYFJI-VAECKANCSA-N (4R,4aR,7aR,12bS)-9,9-dihydroxy-3-methyl-2,4,4a,7a,10,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OC1(CC=C2C[C@@H]3[C@@H]4C=CC([C@H]5[C@@]4(C2=C1O5)CCN3C)=O)O UNIQRGVBLNYFJI-VAECKANCSA-N 0.000 claims 1
- WAZQYCSKBMTMLT-HEGSHODTSA-N (4r,4ar,7s,7ar,12bs)-3,9-dimethyl-1,2,4,4a,7,7a,10,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@@]31C1=C2C(C)(O)CC=C1C4 WAZQYCSKBMTMLT-HEGSHODTSA-N 0.000 claims 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 1
- QIJGACRZQSWKNB-UHFFFAOYSA-N 3-(2-phenylethenyl)benzene-1,2-diol Chemical compound OC1=CC=CC(C=CC=2C=CC=CC=2)=C1O QIJGACRZQSWKNB-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 230000005588 protonation Effects 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000005557 antagonist Substances 0.000 abstract description 3
- 229940035676 analgesics Drugs 0.000 abstract description 2
- 239000000730 antalgic agent Substances 0.000 abstract description 2
- 230000003533 narcotic effect Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- WJZVCRUPHQAKSZ-IPOQPSJVSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-1,2,3,4,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 WJZVCRUPHQAKSZ-IPOQPSJVSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 239000000284 extract Substances 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000002329 infrared spectrum Methods 0.000 description 15
- 238000007254 oxidation reaction Methods 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000003647 oxidation Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- HGPQAWTZLJXCTC-SSTWWWIQSA-N (4r,4ar,7s,7ar,12bs)-7,9-dimethoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline Chemical compound C([C@@H](N(CC1)C)[C@@H]2C=C[C@@H]3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 HGPQAWTZLJXCTC-SSTWWWIQSA-N 0.000 description 10
- YPZPXTZKBNWUTF-QMVVXIJUSA-N (4r,4as,7s,7ar,12bs)-9-methoxy-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol Chemical compound O[C@H]([C@@H]1O2)C=C[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C YPZPXTZKBNWUTF-QMVVXIJUSA-N 0.000 description 10
- 101150041968 CDC13 gene Proteins 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 235000006408 oxalic acid Nutrition 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- ITPKWZOTYLQLCO-DDFUGIKWSA-N OC12C(C=CC=3C[C@@H]4[C@@H]5C=C[C@@H]([C@@H]([C@@]5(C13)CCN4C)O2)O)OC Chemical compound OC12C(C=CC=3C[C@@H]4[C@@H]5C=C[C@@H]([C@@H]([C@@]5(C13)CCN4C)O2)O)OC ITPKWZOTYLQLCO-DDFUGIKWSA-N 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 239000012156 elution solvent Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 150000004965 peroxy acids Chemical class 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- GZCPDDJEPYWGHC-XHIFRZTCSA-N (4R,4aR,7S,7aR,12bS)-9-ethyl-3-methyl-1,2,4,4a,7,7a,10,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@@]31C1=C2C(O)(CC)CC=C1C4 GZCPDDJEPYWGHC-XHIFRZTCSA-N 0.000 description 3
- JSFGIWIHCRVLSN-HTNFSKGQSA-N (4R,4aR,7aR,12bS)-3-methyl-2,4,4a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,7,7a,9-tetrol Chemical compound OC1([C@]2([C@]34C=5C(=C(C=CC=5C[C@H]([C@@H]3C=C1)N(C)CC4)O)O2)O)O JSFGIWIHCRVLSN-HTNFSKGQSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052770 Uranium Inorganic materials 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960001012 codeine hydrochloride Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- FRZOBRSVZWVMFR-KOFBORESSA-N (4R,4aR,7S,7aR,12bS)-9-hydroperoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol Chemical compound O[C@H]([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OO)=CC=C1C4 FRZOBRSVZWVMFR-KOFBORESSA-N 0.000 description 2
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- AMYFCNALAIRPLH-WYIOCLOVSA-N C(C)C1=CC(OC)=C2C=3[C@@]45[C@@H](O2)[C@@H](O)C=C[C@H]4[C@@H](CC1=3)N(C)CC5 Chemical compound C(C)C1=CC(OC)=C2C=3[C@@]45[C@@H](O2)[C@@H](O)C=C[C@H]4[C@@H](CC1=3)N(C)CC5 AMYFCNALAIRPLH-WYIOCLOVSA-N 0.000 description 2
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- ZVTQWXCKQTUVPY-UHFFFAOYSA-N chloromethylcyclopropane Chemical compound ClCC1CC1 ZVTQWXCKQTUVPY-UHFFFAOYSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001035 methylating effect Effects 0.000 description 2
- PFBSOANQDDTNGJ-YNHQPCIGSA-N morphinone Chemical compound O([C@H]1C(C=C[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O PFBSOANQDDTNGJ-YNHQPCIGSA-N 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- DCSLUQHLJGTUSJ-SHRNBREZSA-N (4R,4aR,7S,7aR,12bS)-3-methyl-1,2,4,4a,7,7a,9,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,8a,9-triol Chemical group OC12C(C=CC=3C[C@@H]4[C@@H]5C=C[C@@H]([C@@H]([C@@]5(C1=3)CCN4C)O2)O)O DCSLUQHLJGTUSJ-SHRNBREZSA-N 0.000 description 1
- LJRIQCOECCOZGF-YNHQPCIGSA-N (4R,4aR,7aR,12bS)-9-hydroperoxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OOC=1C=CC=2C[C@@H]3[C@@H]4C=CC([C@H]5[C@@]4(C=2C=1O5)CCN3C)=O LJRIQCOECCOZGF-YNHQPCIGSA-N 0.000 description 1
- ORXWIMVTSMUFKA-XJCQYFIJSA-N (4R,4aS,7aR,12bS)-9-benzyl-4a,9-dihydroxy-3-methyl-1,2,4,7a,10,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound C(C1=CC=CC=C1)C1(CC=C2C[C@@H]3[C@@]4(C=CC([C@H]5[C@@]4(C2=C1O5)CCN3C)=O)O)O ORXWIMVTSMUFKA-XJCQYFIJSA-N 0.000 description 1
- DYXBSXBXZNSAPO-UHFFFAOYSA-M 1,1-dimethylpyrrolidin-1-ium;iodide Chemical compound [I-].C[N+]1(C)CCCC1 DYXBSXBXZNSAPO-UHFFFAOYSA-M 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- LLWADFLAOKUBDR-UHFFFAOYSA-N 2-methyl-4-chlorophenoxybutyric acid Chemical compound CC1=CC(Cl)=CC=C1OCCCC(O)=O LLWADFLAOKUBDR-UHFFFAOYSA-N 0.000 description 1
- QBGXNSBJRUANLZ-UHFFFAOYSA-N 2-methylcyclopropane-1,1-diol Chemical compound CC1CC1(O)O QBGXNSBJRUANLZ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DMGAPZQHWZFIRE-GRGSLBFTSA-N 3-acetyloxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O DMGAPZQHWZFIRE-GRGSLBFTSA-N 0.000 description 1
- IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000005575 MCPB Substances 0.000 description 1
- 101150039283 MCPB gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- ABUYHLHZEPVAGR-UHFFFAOYSA-N [O].[Kr] Chemical compound [O].[Kr] ABUYHLHZEPVAGR-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ONSYTLVODJIYDC-UHFFFAOYSA-N chloroamine;hydrochloride Chemical compound Cl.ClN ONSYTLVODJIYDC-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- ZYCMDWDFIQDPLP-UHFFFAOYSA-N hbr bromine Chemical compound Br.Br ZYCMDWDFIQDPLP-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229950004392 norcodeine Drugs 0.000 description 1
- HKOIXWVRNLGFOR-UHFFFAOYSA-N norcodeine Natural products O1C2C(O)C=CC3C4CC5=CC=C(OC)C1=C5C23CCN4 HKOIXWVRNLGFOR-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- ZDHURYWHEBEGHO-UHFFFAOYSA-N potassiopotassium Chemical compound [K].[K] ZDHURYWHEBEGHO-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/893,464 US5869669A (en) | 1996-07-26 | 1997-07-11 | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW505648B true TW505648B (en) | 2002-10-11 |
Family
ID=25401603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW087116132A TW505648B (en) | 1997-07-11 | 1998-09-29 | Preparation of 14-hydroxynormorphinones, oxycodone noroxymorphone, oxymorphone and naltrexone from normorphinones |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US5869669A (enExample) |
| EP (1) | EP1000065B1 (enExample) |
| JP (1) | JP2001518444A (enExample) |
| KR (1) | KR100363486B1 (enExample) |
| CN (1) | CN1152880C (enExample) |
| AT (1) | ATE291023T1 (enExample) |
| AU (1) | AU740822B2 (enExample) |
| CA (1) | CA2296035C (enExample) |
| DE (1) | DE69829379D1 (enExample) |
| HU (1) | HUP0003918A3 (enExample) |
| IL (1) | IL133792A0 (enExample) |
| IN (1) | IN1998KO01500A (enExample) |
| NO (1) | NO20000111L (enExample) |
| RU (1) | RU2183636C2 (enExample) |
| SK (1) | SK102000A3 (enExample) |
| TR (1) | TR200000033T2 (enExample) |
| TW (1) | TW505648B (enExample) |
| WO (1) | WO1999002529A1 (enExample) |
| ZA (1) | ZA986144B (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912347A (en) * | 1996-09-30 | 1999-06-15 | Mallinckrodt Inc. | Process for preparing a morphinan derivative |
| AU4823900A (en) * | 1999-05-05 | 2000-11-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Direct c-14 oxidation of opioids |
| US6177567B1 (en) * | 1999-10-15 | 2001-01-23 | Boehringer Ingelheim Chemicals, Inc. | Method for preparing oxycodone |
| US7435817B2 (en) * | 2001-08-23 | 2008-10-14 | N.V. Organon | C-14 oxidation of morphine derivatives |
| JP3961796B2 (ja) * | 2001-08-27 | 2007-08-22 | ソニー株式会社 | 情報提供システム、情報処理装置および方法、情報提供装置および方法、記録媒体、並びにプログラム |
| DE10161963A1 (de) * | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| US20040058946A1 (en) * | 2002-07-05 | 2004-03-25 | Buchwald Stephen L. | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals |
| RU2236412C2 (ru) * | 2002-07-18 | 2004-09-20 | Власов Михаил Иванович | Способ получения производных морфинона, способ получения производных 14-гидроксиморфинона, и способ получения производных оксиморфона |
| RU2215741C1 (ru) * | 2002-11-05 | 2003-11-10 | Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" | Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения |
| RU2215742C1 (ru) * | 2002-11-05 | 2003-11-10 | Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" | Способ получения сложных эфиров n-замещенных 14-гидроксиморфинанов |
| US7285665B2 (en) * | 2002-11-08 | 2007-10-23 | Mallinckrodt Inc. | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
| EP2218448B1 (en) | 2002-12-13 | 2015-09-23 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
| US6864370B1 (en) * | 2003-06-05 | 2005-03-08 | Zhaiwei Lin | Process for manufacturing oxycodone |
| US6790959B1 (en) | 2003-06-05 | 2004-09-14 | Halsey Drug Company, Inc. | Process for manufacturing thebaine |
| JP4879740B2 (ja) | 2003-09-22 | 2012-02-22 | ジョンソン、マッセイ、パブリック、リミテッド、カンパニー | モルヒナン化合物およびその中間体の合成法 |
| US7875718B2 (en) * | 2003-09-22 | 2011-01-25 | Johnson Matthey Public Limited Company | Process for the synthesis of morphinane compounds and intermediates thereof |
| DE602005009321D1 (de) * | 2004-02-06 | 2008-10-09 | Euro Celtique Sa | Hinonen und 3-o-geschützten morphinondienolcarboxylaten |
| TWI365880B (en) * | 2004-03-30 | 2012-06-11 | Euro Celtique Sa | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp |
| SK286047B6 (sk) * | 2004-04-13 | 2008-01-07 | Zentiva, A. S. | Spôsob prípravy derivátov 4,5alfa-epoxy-6-oxomorfínanu |
| US6946556B1 (en) * | 2004-05-21 | 2005-09-20 | Acura Pharmaceuticals, Inc. | Preparation of opioid analgesics by a one-pot process |
| WO2005123743A1 (en) * | 2004-06-08 | 2005-12-29 | Mallinckrodt Inc. | Extraction of alkaloids from opium |
| ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
| DK2767292T3 (en) | 2004-09-17 | 2016-12-19 | Durect Corp | RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB |
| GB0421149D0 (en) * | 2004-09-23 | 2004-10-27 | Johnson Matthey Plc | Preparation of oxycodone |
| GB0421687D0 (en) * | 2004-09-30 | 2004-11-03 | Johnson Matthey Plc | Preparation of opiate analgesics |
| WO2006084389A1 (de) * | 2005-02-11 | 2006-08-17 | Cilag Ltd. | Verfahren zur reinigung von noroxymorphon-verbindungen |
| PT1861405E (pt) * | 2005-03-04 | 2009-07-27 | Euro Celtique Sa | Método de diminuír a quantidade de cetonas insaturadas em alfa-beta numa composição de opiáceos |
| RU2397173C2 (ru) * | 2005-04-06 | 2010-08-20 | Торей Индастриз, Инк. | Кристаллические производные морфинана и способ их получения |
| US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| DE602006019246D1 (de) * | 2005-06-16 | 2011-02-10 | Mallinckrodt Inc | Synthetische route zu 14-hydroxylopiaten über 1-halogenthebain oder analoga |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US20070117826A1 (en) * | 2005-11-23 | 2007-05-24 | Forest Laboratories, Inc. | Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone |
| JP5695296B2 (ja) | 2006-03-02 | 2015-04-01 | マリンクロッド エルエルシー | 低レベルのアルファ，ベータ−不飽和ケトン化合物を伴うモルフィナン−６−オン生成物の製造方法 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| EP2099764B1 (en) * | 2006-09-20 | 2011-07-27 | Mallinckrodt Inc. | Preparation of substituted morphinan-6-ones and salts and intermediates thereof |
| AU2012216358B2 (en) * | 2006-10-17 | 2014-11-20 | Penick Corporation | Process For Preparing Oxymorphone, Naltrexone and Buprenorphine |
| CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
| US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
| DK2073636T3 (da) | 2006-10-17 | 2012-11-19 | Penick Corp | Fremgangsmåde til fremstilling af oxymorphon |
| AU2007325918B2 (en) | 2006-11-03 | 2013-10-17 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
| CN101652370A (zh) * | 2006-12-04 | 2010-02-17 | 诺拉姆科有限公司 | 制备14-羟基可待因酮水平减少的羟考酮的方法 |
| ES2378710T3 (es) * | 2006-12-04 | 2012-04-17 | Noramco, Inc. | Procedimiento para reducir impurezas en la base de oxicodona |
| GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
| US9040726B2 (en) * | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
| JP5875748B2 (ja) * | 2007-03-06 | 2016-03-02 | マリンクロッド エルエルシー | 第４級ｎ−アルキルモルフィナンアルカロイド塩の調製のための方法 |
| PL2125824T5 (pl) * | 2007-03-23 | 2024-11-04 | SpecGx LLC | Ulepszony sposób wytwarzania oksymorfonu z oripawiny |
| WO2008130553A1 (en) * | 2007-04-16 | 2008-10-30 | Mallinckrodt Inc. | Novel opiate reduction utilizing catalytic hydrogen transfer reaction |
| WO2008144320A2 (en) * | 2007-05-17 | 2008-11-27 | Endo Pharmaceuticals, Inc. | Opioid and methods of making and using the same |
| EP2067471B1 (en) | 2007-12-06 | 2018-02-14 | Durect Corporation | Oral pharmaceutical dosage forms |
| US8067596B2 (en) | 2007-12-17 | 2011-11-29 | Mallinckrodt Llc | Processes for the production of (+)- “Nal” morphinan compounds |
| CA2709862C (en) * | 2007-12-17 | 2016-03-15 | Peter X. Wang | Sinomenine derivatives and processes for their synthesis |
| ATE519765T1 (de) * | 2008-02-29 | 2011-08-15 | Mallinckrodt Inc | Verfahren zur herstellung von 3-hydroxymorphinan- derivaten |
| EP2291380B1 (en) * | 2008-04-24 | 2011-09-07 | Janssen Pharmaceutica N.V. | Nalmefene prodrugs |
| EP2896614B1 (en) * | 2008-05-27 | 2017-07-12 | Mallinckrodt LLC | Processes and compounds for the preparation of normorphinans |
| WO2010028004A2 (en) | 2008-09-03 | 2010-03-11 | Mallinckrodt Inc. | Substituted berbines and processes for their synthesis |
| CN102227433B (zh) * | 2008-09-30 | 2015-01-07 | 马林克罗特有限公司 | 烷基化吗啡喃衍生物的仲胺基团的方法 |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| CA2936749C (en) | 2010-06-11 | 2019-07-09 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| TWI471289B (zh) | 2010-06-11 | 2015-02-01 | Rhodes Technologies | 使三級胺進行ｎ－脫烷反應之方法 |
| CA2804101C (en) | 2010-07-02 | 2021-01-19 | Johnson Matthey Public Limited Company | Process for the synthesis and purification of oxycodone |
| RU2448709C1 (ru) * | 2011-02-01 | 2012-04-27 | Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) | Способ получения налтрексона |
| TWI560170B (en) * | 2011-12-06 | 2016-12-01 | Lundbeck & Co As H | Process for recovery of nalmefene hydrochloride |
| US9315514B2 (en) | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
| EP2931726B1 (en) | 2012-12-14 | 2017-01-25 | Purdue Pharma LP | Spirocyclic morphinans and their use |
| US8937084B2 (en) | 2012-12-14 | 2015-01-20 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
| ES2631197T3 (es) | 2012-12-14 | 2017-08-29 | Purdue Pharma Lp | Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes |
| CA2896202A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
| EP2941430B1 (en) | 2012-12-28 | 2017-04-26 | Purdue Pharma LP | 7,8-cyclicmorphinan analogs |
| WO2014102591A1 (en) | 2012-12-31 | 2014-07-03 | Rhodes Technologies | PROCESS FOR PREPARING 7β-SUBSTITUTED 6α,14α -ETHENOMORPHINANS AND 7β-SUBSTITUTED 6α,14α-ETHANOMORPHINANS |
| CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
| EP2829541A1 (en) * | 2013-07-26 | 2015-01-28 | Siegfried AG | Novel synthesis of noroxymorphone from morphine |
| EP3027622B8 (en) | 2013-08-02 | 2019-06-12 | Johnson Matthey Public Limited Company | Process for the preparation of oxymorphone |
| EP3087078B1 (en) | 2013-12-26 | 2019-05-15 | Purdue Pharma LP | 7-beta-alkyl analogs of orvinols |
| WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
| WO2015097546A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Propellane-based compounds and their use as opioid receptor modulators |
| US9862726B2 (en) | 2013-12-26 | 2018-01-09 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
| WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
| MX2017006520A (es) | 2014-11-25 | 2017-08-09 | Kempharm Inc * | Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico. |
| EP3252055B1 (en) | 2016-05-31 | 2018-09-19 | Alcaliber Investigacion Desarrollo e Innovacion SLU | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| CN109475505A (zh) | 2016-07-06 | 2019-03-15 | 度瑞公司 | 具有药物组成物、屏障层及药物层的口服剂型 |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
| SK592017A3 (sk) | 2017-07-04 | 2019-01-08 | Saneca Pharmaceuticals A. S. | Spôsob prípravy morfínanových zlúčenín |
| CA3091826A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
| CN110054656B (zh) * | 2019-05-28 | 2021-02-02 | 宜昌人福药业有限责任公司 | 一种10-羰基/羟基吗啡-6-葡萄糖苷酸的合成方法 |
| CA3146163A1 (en) | 2019-07-08 | 2021-01-14 | University Of Health Sciences & Pharmacy In St. Louis | G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment |
| WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| CN114621239B (zh) * | 2020-12-10 | 2026-02-03 | 鲁南制药集团股份有限公司 | 一种纳曲酮的制备方法 |
| JP7773548B2 (ja) * | 2020-12-28 | 2025-11-19 | ナヴィン サクセナ リサーチ アンド テクノロジー ピーブイティー．エルティーディー． | モルヒネからのノルオキシモルフォンの合成のための新規方法 |
| CA3203561A1 (en) | 2021-01-12 | 2022-07-21 | Adrian Neil Verity | Sustained release drug delivery systems and related methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3819636A (en) * | 1970-09-15 | 1974-06-25 | American Home Prod | 4a,10-(methaniminomethano)phenanthrene derivatives |
| US4795813A (en) * | 1981-08-17 | 1989-01-03 | The Florida Board Of Regents On Behalf Of The Florida State University | Synthesis of derivatives of codeine and other 3-O-alkylmorphines |
| US5112975A (en) * | 1984-03-27 | 1992-05-12 | Mallinckrodt Specialty Chemicals Company | Preparation of noroxymorphone from morphine |
| DE3581423D1 (de) * | 1984-03-27 | 1991-02-28 | Mallinckrodt Inc | Herstellung von noroxymorphon aus morphin. |
| US4639520A (en) * | 1984-03-27 | 1987-01-27 | Mallinckrodt, Inc. | Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone |
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| US4912114A (en) * | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
-
1997
- 1997-07-11 US US08/893,464 patent/US5869669A/en not_active Expired - Fee Related
-
1998
- 1998-07-10 RU RU2000100062/04A patent/RU2183636C2/ru not_active IP Right Cessation
- 1998-07-10 CN CNB988088169A patent/CN1152880C/zh not_active Expired - Fee Related
- 1998-07-10 EP EP98934213A patent/EP1000065B1/en not_active Revoked
- 1998-07-10 DE DE69829379T patent/DE69829379D1/de not_active Expired - Lifetime
- 1998-07-10 AU AU83791/98A patent/AU740822B2/en not_active Ceased
- 1998-07-10 SK SK10-2000A patent/SK102000A3/sk unknown
- 1998-07-10 WO PCT/US1998/013592 patent/WO1999002529A1/en not_active Ceased
- 1998-07-10 TR TR2000/00033T patent/TR200000033T2/xx unknown
- 1998-07-10 CA CA002296035A patent/CA2296035C/en not_active Expired - Fee Related
- 1998-07-10 KR KR20007000252A patent/KR100363486B1/ko not_active Expired - Fee Related
- 1998-07-10 AT AT98934213T patent/ATE291023T1/de not_active IP Right Cessation
- 1998-07-10 IL IL13379298A patent/IL133792A0/xx unknown
- 1998-07-10 ZA ZA986144A patent/ZA986144B/xx unknown
- 1998-07-10 JP JP2000502051A patent/JP2001518444A/ja active Pending
- 1998-07-10 HU HU0003918A patent/HUP0003918A3/hu unknown
- 1998-07-16 US US09/116,282 patent/US6013796A/en not_active Expired - Fee Related
- 1998-07-16 US US09/116,286 patent/US5952495A/en not_active Expired - Fee Related
- 1998-07-16 US US09/116,285 patent/US6008354A/en not_active Expired - Fee Related
- 1998-07-16 US US09/116,284 patent/US5922876A/en not_active Expired - Fee Related
- 1998-07-16 US US09/116,283 patent/US6008355A/en not_active Expired - Fee Related
- 1998-07-17 US US09/118,577 patent/US5948788A/en not_active Expired - Fee Related
- 1998-08-21 IN IN1500KO1998 patent/IN1998KO01500A/en unknown
- 1998-09-29 TW TW087116132A patent/TW505648B/zh not_active IP Right Cessation
-
2000
- 2000-01-10 NO NO20000111A patent/NO20000111L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1028025A1 (en) | 2001-02-02 |
| EP1000065A1 (en) | 2000-05-17 |
| AU740822B2 (en) | 2001-11-15 |
| US5948788A (en) | 1999-09-07 |
| CA2296035A1 (en) | 1999-01-21 |
| NO20000111L (no) | 2000-02-25 |
| EP1000065A4 (en) | 2001-09-12 |
| CN1272845A (zh) | 2000-11-08 |
| US6008355A (en) | 1999-12-28 |
| HUP0003918A3 (en) | 2003-04-28 |
| WO1999002529A1 (en) | 1999-01-21 |
| EP1000065B1 (en) | 2005-03-16 |
| US6013796A (en) | 2000-01-11 |
| IN1998KO01500A (enExample) | 2005-03-11 |
| RU2183636C2 (ru) | 2002-06-20 |
| TR200000033T2 (tr) | 2000-12-21 |
| US6008354A (en) | 1999-12-28 |
| US5952495A (en) | 1999-09-14 |
| KR100363486B1 (ko) | 2002-12-16 |
| CA2296035C (en) | 2004-04-13 |
| KR20010021693A (ko) | 2001-03-15 |
| NO20000111D0 (no) | 2000-01-10 |
| SK102000A3 (en) | 2000-07-11 |
| US5869669A (en) | 1999-02-09 |
| US5922876A (en) | 1999-07-13 |
| JP2001518444A (ja) | 2001-10-16 |
| HUP0003918A2 (hu) | 2001-07-30 |
| ATE291023T1 (de) | 2005-04-15 |
| IL133792A0 (en) | 2001-04-30 |
| CN1152880C (zh) | 2004-06-09 |
| ZA986144B (en) | 1999-05-19 |
| AU8379198A (en) | 1999-02-08 |
| DE69829379D1 (de) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5952495A (en) | Preparation of 14-hydroxynormorphinones from normorphinones | |
| JP2001518444A5 (enExample) | ||
| AU2002227135B2 (en) | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents | |
| US5668285A (en) | Total synthesis of northebaine, normophine, noroxymorphone enantiomers and derivatives via N-Nor intermediates | |
| KR101115841B1 (ko) | 4-하이드록시벤조모르판 | |
| US8541586B2 (en) | Large substituent, non-phenolic opioids and methods of use thereof | |
| CA2694497A1 (en) | Quaternary opioid carboxamides | |
| EP1664061B1 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| CA2686851A1 (en) | Fused-ring heterocycle opioids | |
| CA2501389C (en) | Remedies or preventives for frequent urination or urinary incontinence and morphinan derivatives having nitrogen-containing heterocyclic group | |
| JP2012524726A (ja) | モルフィナンおよびモルフィノン化合物の調製法 | |
| CA2731429A1 (en) | Large substituent, non-phenolic amine opioids | |
| US20110098474A1 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| JP2002513007A (ja) | アリール縮合アザ多環式化合物 | |
| HK1028025B (en) | Preparation of oxymorphone, oxycodone and derivatives | |
| Beller | Syntheses directed toward the construction of 1-deaza-1-thialysergic acid | |
| AU2004274038A1 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
| HK1063803A1 (en) | Process for the preparation of a 14-hydroxynormorphinone derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |